To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
67
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Miami Research Associates
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Springfield, Missouri, United States
Research Site
Berlin, Germany
Lutenising Hormone (LH) AUC(0-8) Ratio to Baseline at Day 7
Change-from-baseline of luteinising hormone area under the concentration-time curve from time zero to 8 hours postdose \[AUC(0-8)\] at Day 7
Time frame: Day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Belfast, United Kingdom
Research Site
Edinburgh, United Kingdom
Research Site
London, United Kingdom